Identification of mutations in receptor and non-receptor protein kinases that drive malignant transformation of cancer cells ('driver'mutations) have revolutionized patient care by opening the door to patient-tailored targeted therapies that can improve patient survival. In order to discover new targets for therapy, we sequenced the coding regions of -100 melanomas and identified a large number of somatic mutations and inherited Single Nucleotide Variants (SNVs). One of the most important findings of this effort is the identification ofthe """"""""RAC1 signaling pathway"""""""" as a potential new target for melanoma therapy. The analysis revealed a recurrent, UV signature activating mutation in this RHO family of small GTPases, RAC[P29S], in ~5% of melanomas, in addition, the sequencing data revealed mutations in upstream regulators and downstream effectors of RAC1 pathway in a large numbers of melanoma tumors. Functional studies demonstrated an important role in proliferation and migration of not only mutant but also melanoma cells that that donot harbor the P29S mutation. The data suggest that pharmacological inhibition of RACl or its critical effeGtor(s) can be applied for development of new therapies for melanoma patients. The general goals ofthis project are to determine the frequency and prognostic significance of RAC[P29S] mutation in sun exposed melanocytic lesions, and to identify downstream effectors of RACl most likely to be druggable targets in this pathway.
The specific aims are:
Aim 1 : To determine the frequency of RAC1[P29S] mutation and RACl expression levels in a large cohort of melanocytic lesions and correlate with pathological features and tumor progression;
Aim 2 : To elucidate the downstream targets of activated RACl in melanomas.
Aim 3 : To identify small-molecule inhibitors of PAK kinases, the RACl effectors. These studies are likely to provide new opportunities for drug discovery for melanomas and possibly other cancers that can facilitate patienttailored targeted therapy.
There is a need for new patient-tailored therapy for melanoma. Treatment of melanoma patients carrying BRAF[V600E/K] mutations with vemurafenib (PLX4032/RG7204), renamed Zelboraf, yields a very high response rate, but the disease tends to relapse. The novel regulatory pathway discovered by exome sequencing and validated by functional analyses provides the opportunity for additional therapeutic targets for patients who do not benefit from current therapies.
|Kluger, Harriet M; Zito, Christopher R; Turcu, Gabriela et al. (2017) PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res 23:4270-4279|
|Cyrenne, Benoit M; Lewis, Julia M; Weed, Jason G et al. (2017) Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 130:2073-2083|
|Weed, Jason; Gibson, Juliet; Lewis, Julia et al. (2017) FISH Panel for Leukemic CTCL. J Invest Dermatol 137:751-753|
|Lazova, Rossitza; Pornputtapong, Natapol; Halaban, Ruth et al. (2017) Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas. Mod Pathol 30:640-649|
|Zhang, Yanchang; Cartmel, Brenda; Choy, Courtney C et al. (2017) Body mass index, height and early-onset basal cell carcinoma in a case-control study. Cancer Epidemiol 46:66-72|
|Cartmel, B; Bale, A E; Mayne, S T et al. (2017) Predictors of tanning dependence in white non-Hispanic females and males. J Eur Acad Dermatol Venereol 31:1223-1228|
|Stiegler, Amy L; Boggon, Titus J (2017) p190RhoGAP proteins contain pseudoGTPase domains. Nat Commun 8:506|
|Wu, Mengyun; Zang, Yangguang; Zhang, Sanguo et al. (2017) Accommodating missingness in environmental measurements in gene-environment interaction analysis. Genet Epidemiol 41:523-554|
|Kahn, Jessica A; Lee, Jeannette; Belzer, Marvin et al. (2017) HIV-Infected Young Men Demonstrate Appropriate Risk Perceptions and Beliefs about Safer Sexual Behaviors after Human Papillomavirus Vaccination. AIDS Behav :|
|Miller, Chad J; Muftuoglu, Yagmur; Turk, Benjamin E (2017) A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases. Biochem Pharmacol 142:39-45|
Showing the most recent 10 out of 147 publications